Yohei Doi MD
Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Join to View Full Profile
3601 5th Ave"# Falk"Pittsburgh, PA 15213
Phone+1 412-648-6401
Fax+1 412-648-6399
Are you Dr. Doi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Yohei Doi, MD is an infectious disease specialist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is an Assistant Professor at University of Pittsburgh School of Medicine.
Education & Training
UPMC Medical EducationFellowship, Infectious Disease, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2003 - 2005
Nagoya University - School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2005 - 2026- PA State Medical License 2008 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLdetected in the SCORPIO-SR phase 3 trial.Takeki Uehara, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato
Antiviral Research. 2025-04-01 - Molecular analysis of AmpC-producing Escherichia coli isolated from pediatric patients.Eiki Ogawa, Masahiro Suzuki, Aki Sakurai, Yohei Doi
Journal of the Pediatric Infectious Diseases Society. 2025-03-12 - A case of fatal disseminated infection with masticator space abscess caused by ESBL-producing K57-ST412 hypervirulent Klebsiella pneumoniae.Kohei Ukai, Yoshitaka Tomoda, Satoe Ishii, Satoshi Nakazato, Yohei Doi
Journal of Infection and Chemotherapy. 2025-03-01
Press Mentions
Fujita Health University Favipiravir Trial Evidences No Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?July 11th, 2020- WHO Studies File International Each Day Coronavirus Circumstances Improve: LiveJuly 10th, 2020
No Pause in Coronavirus Trial for Avigan, Japan's Lead Researcher SaysMay 20th, 2020- Join now to see all
Grant Support
- Colistin resistance in extensively drug-resistant Gram-negative pathogensUNIVERSITY OF PITTSBURGH AT PITTSBURGH2014–2025
